These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12742999

  • 1. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW, REgression GRowth Evaluation Statin Study Group.
    Circulation; 2003 May 20; 107(19):2416-21. PubMed ID: 12742999
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events.
    Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D.
    Arterioscler Thromb Vasc Biol; 2003 Dec 20; 23(12):e61-4. PubMed ID: 14563652
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
    de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA.
    J Am Coll Cardiol; 2004 Mar 03; 43(5):854-7. PubMed ID: 14998629
    [Abstract] [Full Text] [Related]

  • 6. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
    Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, Anderson JL.
    Am Heart J; 2003 Dec 03; 146(6):1007-14. PubMed ID: 14660992
    [Abstract] [Full Text] [Related]

  • 7. Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
    Di Nisio M, Di Febbo C, Moretta V, Guglielmi MD, Stuppia L, Cuccurullo F, Porreca E.
    Thromb Haemost; 2007 Sep 03; 98(3):642-6. PubMed ID: 17849054
    [Abstract] [Full Text] [Related]

  • 8. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction.
    Edfeldt K, Bennet AM, Eriksson P, Frostegård J, Wiman B, Hamsten A, Hansson GK, de Faire U, Yan ZQ.
    Eur Heart J; 2004 Aug 03; 25(16):1447-53. PubMed ID: 15302104
    [Abstract] [Full Text] [Related]

  • 9. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE.
    Am J Cardiol; 2005 Sep 05; 96(5A):61F-68F. PubMed ID: 16126025
    [Abstract] [Full Text] [Related]

  • 10. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB.
    Fortschr Med; 1996 Mar 20; 114(8):91-8. PubMed ID: 8647574
    [Abstract] [Full Text] [Related]

  • 11. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H.
    J Natl Cancer Inst; 2005 Apr 06; 97(7):525-32. PubMed ID: 15812078
    [Abstract] [Full Text] [Related]

  • 12. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
    Marschang P, Sandhofer A, Ritsch A, Fiŝer I, Kvas E, Patsch JR.
    J Intern Med; 2006 Aug 06; 260(2):151-9. PubMed ID: 16882279
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
    Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ.
    Circulation; 2005 Jan 25; 111(3):278-87. PubMed ID: 15655129
    [Abstract] [Full Text] [Related]

  • 17. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study.
    Morange PE, Tiret L, Saut N, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Juhan-Vague I, PRIME Study Group.
    Eur J Hum Genet; 2004 Dec 25; 12(12):1041-9. PubMed ID: 15367917
    [Abstract] [Full Text] [Related]

  • 18. The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis.
    Hommels MJ, Kroon AA, Netea MG, de Leeuw PW, Bruggeman CA, Leiner T, Koster DA, Stalenhoef AF, van der Ven AJ.
    Neth J Med; 2007 Jun 25; 65(6):203-7. PubMed ID: 17587646
    [Abstract] [Full Text] [Related]

  • 19. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M.
    Circulation; 2004 Sep 21; 110(12):1557-63. PubMed ID: 15364796
    [Abstract] [Full Text] [Related]

  • 20. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC, Mamdani MM.
    Circulation; 2005 Aug 30; 112(9):1296-300. PubMed ID: 16116054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.